FDA Weighs Psychedelic Therapy Standards

The U.S. Food and Drug Administration (FDA) recently convened a public meeting to discuss safety and access standards for psychedelic therapies. This gathering is part of an ongoing effort to accelerate the development of treatments derived from compounds like ibogaine and psilocybin, despite their current Schedule I controlled substance classification.

These psychedelic-derived treatments are primarily being explored for severe depression and post-traumatic stress disorder in patients unresponsive to conventional therapies. Early trials are also investigating their efficacy for substance abuse disorders, borderline personality disorder, and anxiety.

Globally, some countries have already authorized psychedelic treatments. Australia permits synthetic MDMA for PTSD and psilocybin for treatment-resistant depression. Switzerland offers limited psilocybin psychotherapy, while Jamaica allows over-the-counter psilocybin products. Brazil and the Netherlands permit plant-based psychedelics, and Mexico is a destination for ibogaine treatment.

In the United States and Europe, psilocybin is a leading candidate for treating depression, with trials demonstrating significant symptom reduction. Johnson & Johnson's esketamine nasal spray is approved for treatment-resistant depression and suicidal ideation. Lykos Therapeutics' MDMA therapy for PTSD showed promising results, but the FDA requested an additional trial due to methodological concerns.

Potential risks of psychedelic-assisted therapy include acute anxiety, confusion, and temporary mood worsening. More serious risks, such as psychosis, can occur, particularly in individuals with a predisposition. Physical side effects like nausea and cardiac issues have also been noted, with risks generally higher outside clinical settings.